Provided by Tiger Trade Technology Pte. Ltd.

INVESCO PHARMACEUTICALS ETF

120.88
-0.3600-0.30%
Post-market: 120.880.00000.00%19:30 EDT
Volume:21.60K
Turnover:2.61M
Market Cap:545.17M
PE:6.27
High:121.66
Open:121.66
Low:120.55
Close:121.24
52wk High:131.68
52wk Low:92.10
Shares:4.51M
Float Shares:4.51M
Volume Ratio:0.46
T/O Rate:0.48%
Dividend:1.11
Dividend Rate:0.92%
EPS(TTM):19.29
EPS(LYR):21.73
ROE:23.89%
ROA:0.60%
PB:1.64
PE(LYR):5.56

Loading ...

J&J Says Imaavy Shows Sustained Disease Control Through Two Years in Adolescent Myasthenia Gravis Study

Reuters
·
Sep 29

J&J - no New Safety Signals Identified Through Two Years of Imaavy Treatment

THOMSON REUTERS
·
Sep 29

J&J - Presents New Data on Imaavy in Generalized Myasthenia Gravis

THOMSON REUTERS
·
Sep 29

J&J - Two-Year Phase 2/3 Data Shows Sustained Disease Control and Reduced Corticosteroid Use in Adolescents

THOMSON REUTERS
·
Sep 29

Eli Lilly Reports Zepbound Showed 4.5% Greater Weight Loss Than Novo Nordisk's Wegovy HD

MT Newswires Live
·
Sep 29

Wall Street Analysts Are Bullish on Top Healthcare Picks

TIPRANKS
·
Sep 29

Eli Lilly’s Zepbound shows improved weight loss vs. Wegovy in new analysis

TIPRANKS
·
Sep 29

Eli Lilly - Zepbound 10 Mg and 15 Mg Show Comparable Adverse Event Discontinuation Rates to Wegovy Hd

THOMSON REUTERS
·
Sep 29

Eli Lilly - Zepbound 15 Mg Shows 4.5% Greater Weight Loss than Wegovy Hd in Adults with Obesity

THOMSON REUTERS
·
Sep 29

Lilly's Zepbound (Tirzepatide 10 Mg and 15 Mg) was Associated with More Weight Loss than Wegovy Hd (Semaglutide Injection 7.2 Mg) in a New Indirect Treatment Comparison

THOMSON REUTERS
·
Sep 29

Eli Lilly - Zepbound Achieves 20.2% Weight Reduction vs 13.7% for Wegovy at 72 Weeks

THOMSON REUTERS
·
Sep 29

Eli Lilly - Zepbound 15 Mg Users Have over Three Times the Odds of 20% Weight Reduction vs Wegovy Hd

THOMSON REUTERS
·
Sep 29

Lilly Touts Foundayo Advantage over Novo's Ozempic Pill in Diabetes Analysis

Reuters
·
Sep 29

Analysts’ Top Healthcare Picks: AbbVie (ABBV), Quantum-Si (QSI)

TIPRANKS
·
Sep 29

Novo Nordisk Says Ozempic Shows Lower Risk of Cardiovascular Events Compared to Eli Lilly's Mounjaro

Reuters
·
Sep 29

Eli Lilly announces positive results from study of Foundayo 17.2 mg

TIPRANKS
·
Sep 29

Eli Lilly's Foundayo 17.2 Mg was Associated with 1.5% Greater Weight Loss at 52 Weeks

Reuters
·
Sep 29

Lilly Says Foundayo 17.2 Mg Outperforms Oral Semaglutide 25 Mg on Weight Loss, A1C in Indirect Comparison Study

Reuters
·
Sep 29

Eli Lilly - Foundayo 17.2 Mg Shows 1.5% Greater Weight Loss and 0.3% Greater A1c Reduction at 52 Weeks

THOMSON REUTERS
·
Sep 29

Judge Rejects Pfizer, BioNTech, and Moderna Bid to Dismiss Monsanto mRNA Patent Lawsuit

Stock News
·
Sep 29